Biogen’s Swiss Head on Benefits of Diverse Experience…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before…
Tagged with Biogen
What Three Pharma Leaders Want to Share About Switzerland
PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their…
Aducanumab edges closer to Potential Approval: Next up, the…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…
Moving the Needle on Gender Diversity in Swiss Pharma Leadership
While Switzerland has Europe's second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and…
Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…
Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
Luis Calderon – General Manager, Biogen Mexico
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and…
Worried About Biogen’s Aducanumab? Don’t Be
Dr Neil Cashman examines the recent news around Biogen's Alzheimer's treatment aducanumab, assuages some investor fears, and underlines the…
Alzheimer’s Disease Treatment: Canadian-Led Innovation…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen's aducanumab on the search for Alzheimer's Disease (AD) treatments, and…
Biogen Canada’s Marina Vasiliou: A 100% Commitment to…
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied career at MSD in a wide variety of…
